The targeting of anionized polyvinylpyrrolidone to the renal system

被引：55

作者：

Kodaira, H ^{[1
]}

Tsutsumi, Y ^{[1
]}

Yoshioka, Y ^{[1
]}

Kamada, H ^{[1
]}

Kaneda, Y ^{[1
]}

Yamamoto, Y ^{[1
]}

Tsunoda, S ^{[1
]}

Okamoto, T ^{[1
]}

Mukai, Y ^{[1
]}

Shibata, H ^{[1
]}

Nakagawa, S ^{[1
]}

Mayumi, T ^{[1
]}

机构：

[1] Osaka Univ, Dept Biopharmaceut, Grad Sch Pharmaceut Sci, Suita, Osaka 5650871, Japan

来源：

BIOMATERIALS | 2004年 / 25卷 / 18期

关键词：

polyvinvlpyrrolidone (PVP); renal targeting; drug carrier; bioconjugation;

D O I：

10.1016/j.biomaterials.2003.10.097

中图分类号：

R318 [生物医学工程];

学科分类号：

0831 ;

摘要：

We reported that the co-polymer composed of vinylpyrrolidone and maleic acid selectively distributed into the kidneys after i.v. injection. To further optimize the renal drug delivery system, we assessed the renal targeting capability of anionized polyvinylpyrrolidone (PVP) derivatives after intravenous administration in mice. The elimination of anionized PVP derivatives from the blood decreased with increasing anionic groups, and the clearance of carboxylated PVP and sulfonated PVP from the blood was almost similar. But carboxylated PVP efficiently accumulated in the kidney, whereas sulfonated PVP was rapidly excreted in the urine. The renal levels of carboxylated PVP were about five-fold higher than sulfonated PVP. Additionally, carboxylated PVP was effectively taken up by the renal proximal tubular epithelial cells in vivo after i.v. injection. These anionized PVP derivatives did not show any; cytotoxicity against renal tubular cells and endothelial cells in vitro. Thus, these carboxylated and sulfonated PVPs may be useful polymeric carriers for drug delivery to the kidney and bladder, respectively. (C) 2003 Elsevier Ltd. All rights reserved.

引用

页码：4309 / 4315

页数：7

共 14 条

[1] PERMSELECTIVITY OF GLOMERULAR CAPILLARY WALL .3. RESTRICTED TRANSPORT OF POLYANIONS [J].

CHANG, RLS ;

DEEN, WM ;

ROBERTSON, CR ;

BRENNER, BM .

KIDNEY INTERNATIONAL, 1975, 8 (04) :212-218

[2]

ELFARRA AA, 1995, J PHARMACOL EXP THER, V274, P1298

[3] Potentials and limitations of the low-molecular-weight protein lysozyme as a carrier for renal drug targeting [J].

Haverdings, RFG ;

Haas, M ;

Greupink, AR ;

de Vries, PAM ;

Moolenaar, F ;

de Zeeuw, D ;

Meijer, DKF .

RENAL FAILURE, 2001, 23 (3-4) :397-409

[4] SYNTHESIS OF A SUPEROXIDE-DISMUTASE DERIVATIVE THAT CIRCULATES BOUND TO ALBUMIN AND ACCUMULATES IN TISSUES WHOSE PH IS DECREASED [J].

INOUE, M ;

EBASHI, I ;

WATANABE, N ;

MORINO, Y .

BIOCHEMISTRY, 1989, 28 (16) :6619-6624

[5] Serum creatinine levels in the US population: Third National Health and Nutrition Examination Survey [J].

Jones, CA ;

McQuillan, GM ;

Kusek, JW ;

Eberhardt, MS ;

Herman, WH ;

Coresh, J ;

Salive, M ;

Jones, CP ;

Agodoa, LY .

AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 32 (06) :992-999

[6] Synthesis of a poly(vinylpyrrolidone-co-dimethyl maleic anhydride) co-polymer and its application for renal drug targeting [J].

Kamada, H ;

Tsutsumi, Y ;

Sato-Kamada, K ;

Yamamoto, Y ;

Yoshioka, Y ;

Okamoto, T ;

Nakagawa, S ;

Nagata, S ;

Mayumi, T .

NATURE BIOTECHNOLOGY, 2003, 21 (04) :399-404

[7]

Kamada H, 2000, CANCER RES, V60, P6416

[8]

Kaneda Y, 1998, CANCER RES, V58, P290

[9]

*NAT I DIAB DIG KI, 1999, PROGR PRIOR REN DIS

[10] RENAL ACCUMULATION OF STREPTAVIDIN - POTENTIAL USE FOR TARGETED THERAPY TO THE KIDNEY [J].

SCHECHTER, B ;

ARNON, R ;

COLAS, C ;

BURAKOVA, T ;

WILCHEK, M .

KIDNEY INTERNATIONAL, 1995, 47 (05) :1327-1335

← 1 2 →